Aphria gets price target raise to $13.00 at Clarus Securities

A better than expected quarter has Clarus analyst Noel Atkinson raising his price target on Aphria (TSXV:APH).

On Wednesday, Aphria reported its Q4 and fiscal 2017 results. In the fourth quarter, the company lost $2.6-million on revenue of $5.7-million, a topline that was up 106 per cent over the same period last year.

CURE Pharmaceutical & Therapix Biosciences Signs MOU with Israel’s Assuta Medical Centers to Develop First-in-Class Therapeutic Products in Fields of Personalized Medicine & Cannabinoids

CURE Pharmaceutical (OTCQB:CURR), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company and Therapix Biosciences (Nasdaq: TRPX ), a specialty clinical-stage pharmaceutical company dedicated to the development of cannabinoid-based drugs headquartered in Israel, announced today that they signed a memorandum of understanding (MOU) to enter into a research collaboration with Assuta Medical Centers Ltd. 

Medical Marijuana, Inc. Announces Largest Revenue Quarter and Sales Month in Company History, 269% Revenue Increase From Q2 2016

Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States , today announced that the second quarter of 2017 generated the largest revenue quarter in the Company's history. Additionally, the Company celebrated the largest-ever single month of revenue in June 2017 as well as the largest sales month and quarter for wholly owned subsidiary Kannaway.

Here’s A Look At Some Risks When Investing In Marijuana Stocks

Marijuana stocks are flying high right now. There’s no reason to think that 2017 won’t be yet another great year, right? Actually, some significant threats remain for the now-thriving marijuana industry. Here are three of the biggest risks for marijuana stocks this year.